{"gene":"MFAP5","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1996,"finding":"MP25 (MAGP-2/MFAP5) was identified as a distinct component of elastin-associated microfibrils by immunofluorescence and immunoelectron microscopy. Its primary structure contains 173 amino acids with significant homology to MAGP-1 confined to a central 60-amino acid cysteine-rich region (7 conserved cysteines), and it contains an RGD motif but lacks proline-, glutamine-, and tyrosine-rich sequences and hydrophobic carboxyl terminus characteristic of MAGP-1, suggesting distinct functions.","method":"Peptide sequencing, cDNA cloning, immunofluorescence, immunoelectron microscopy, sequence homology analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct protein isolation, molecular cloning, and immunoelectron microscopy localizing the protein to microfibrils; foundational characterization study","pmids":["8557636"],"is_preprint":false},{"year":1998,"finding":"MAGP-2 (MFAP5) is specifically associated with fibrillin-containing microfibrils in multiple tissues (nuchal ligament, dermis, adventitia, glomerular mesangium, perimysium) as confirmed by immunoelectron microscopy, but has a more restricted tissue distribution than MAGP-1, being absent from medial layer of fetal thoracic aorta and ocular zonule where MAGP-1 is present.","method":"Immunoelectron microscopy, immunolocalization, Northern blotting","journal":"The journal of histochemistry and cytochemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — immunoelectron microscopy providing direct ultrastructural localization, replicated across multiple tissue types","pmids":["9671438"],"is_preprint":false},{"year":2002,"finding":"MAGP-2 (MFAP5) specifically interacts with fibrillin-1 and fibrillin-2 via a calcium-binding EGF-like repeat-containing region near the C-terminus of the fibrillins. Binding occurs through a core region of MAGP-2 containing 7 conserved cysteine residues. The fibrillin-1 binding site for MAGP-2 is distinct from the MAGP-1 binding site on fibrillin-1. Interaction was confirmed by co-immunoprecipitation from transfected COS-7 cells.","method":"Yeast two-hybrid library screen, deletion analysis, co-immunoprecipitation from transfected COS-7 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — yeast two-hybrid with deletion mapping plus reciprocal co-IP in mammalian cells, two orthogonal methods in one study","pmids":["12122015"],"is_preprint":false},{"year":2002,"finding":"MAGP-2 (MFAP5) contains a matrix-binding domain similar to the 54-amino acid C-terminal cysteine-rich domain of MAGP-1, but a single amino acid change prevents MAGP-2 from associating with the ECM in the same mammalian cell model used to demonstrate MAGP-1 matrix binding.","method":"Deletion constructs expressed in mammalian cells, GFP fusion localization","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional domain analysis in cell system, single lab, but directly identifies the critical domain difference between MAGP-1 and MAGP-2 matrix binding","pmids":["11796718"],"is_preprint":false},{"year":2005,"finding":"MAGP-2 (MFAP5) interacts with the Notch ligand Jagged1 via the EGF-like repeats of Jagged1, and promotes shedding of the Jagged1 extracellular domain in a metalloproteinase-dependent manner (blocked by hydroxamate inhibitor BB3103). MAGP-2 also interacts with Jagged2 and Delta1 but does not facilitate their shedding. MAGP-1 interacts with DSL ligands but cannot facilitate Jagged1 shedding.","method":"Yeast two-hybrid, co-immunoprecipitation, conditioned media analysis, metalloproteinase inhibitor treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — yeast two-hybrid plus co-IP plus functional shedding assay, three orthogonal methods in one study","pmids":["15788413"],"is_preprint":false},{"year":2006,"finding":"MAGP-2 (MFAP5) directly interacts with the EGF-like repeats of Notch1, and co-expression of MAGP-2 with Notch1 leads to cell surface release of the Notch1 extracellular domain and subsequent activation of Notch signaling. The C-terminal domain of MAGP-2 is required for Notch1 binding and activation. Notch1 extracellular domain release by MAGP-2 requires furin-like cleavage for Notch1 heterodimer formation but does not require subsequent ADAM metalloprotease cleavage.","method":"Co-expression studies, Notch signaling reporter assays, domain deletion analysis, cell surface release assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple functional assays including domain mapping and mechanistic dissection of cleavage requirements, single lab but multiple orthogonal methods","pmids":["16492672"],"is_preprint":false},{"year":2006,"finding":"Microfibril-associated MAGP-2 (MFAP5) stimulates elastic fiber assembly independently of extracellular tropoelastin levels. Electron microscopy showed MAGP-2 specifically associates with microfibrils and elastin globules co-localize with MAGP-2-associated microfibrils. The RGD motif of MAGP-2 is not required for this stimulation of elastic fiber assembly, ruling out integrin receptor binding as the mechanism. MAGP-2 overexpression did not change levels of fibrillin-1, MAGP-1, fibulin-2, fibulin-5, or emilin-1.","method":"Doxycycline-regulated conditional overexpression system, immunofluorescence, electron microscopy, mutation analysis of RGD motif","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro functional reconstitution with electron microscopy confirmation and mutagenesis control, single lab","pmids":["17099216"],"is_preprint":false},{"year":2008,"finding":"MAGP-2 (MFAP5) promotes angiogenic cell sprouting by antagonizing Notch signaling in endothelial cells specifically: MAGP-2 decreased basal and Jagged1-induced Hes-1 promoter activity and blocked Jagged1-stimulated Notch1 receptor processing in endothelial cells, but increased Hes-1 promoter activity in heterologous cell types. Constitutive activation of Notch blocked MAGP-2-promoted angiogenic sprouting.","method":"Hes-1 promoter luciferase reporter assay, Notch1 receptor processing assay in transfected 293T cells, angiogenic sprouting assay, constitutively active Notch rescue experiment","journal":"Microvascular research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple functional assays including epistasis (constitutive Notch blocks MAGP-2 effect), single lab but orthogonal approaches","pmids":["18417156"],"is_preprint":false},{"year":2013,"finding":"MAGP2 (MFAP5) binds active TGFβ1, TGFβ2, and BMP2 in solid phase binding assays. Loss of MAGP2 in Mfap5-/- mice causes neutropenia (contrasting with monocytopenia in MAGP1-deficient mice), and MAGP1;MAGP2 double knockout mice show age-dependent aortic dilation, indicating shared primary functions of MAGPs in large vessel integrity.","method":"Solid phase binding assay, targeted gene inactivation (Mfap5-/- mice), blood cell counts, vascular compliance measurements","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic loss-of-function with defined cellular phenotypes plus direct in vitro binding assay, multiple phenotypes characterized","pmids":["23963447"],"is_preprint":false},{"year":2014,"finding":"MFAP5 (MAGP-2) binding to microfibrils requires its conserved Matrix Binding Domain, and this matrix association is positively regulated by proprotein convertase (PC) cleavage of MAGP2. Mutation of the MAGP2 PC consensus site reduced matrix-associated MAGP2. The C-terminal 20-amino acid domain defined by the PC cleavage site also positively modulates matrix localization in a manner requiring the amino-terminal half of the protein.","method":"Immunofluorescence co-localization with fibrillin-2 microfibrils, PC consensus site mutagenesis, deletion analysis, overexpression in T3 ovarian cells","journal":"Matrix biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus deletion analysis plus immunofluorescence, single lab, cell-based system","pmids":["25153248"],"is_preprint":false},{"year":2014,"finding":"MFAP5 (MAGP-2) activates FAK/CREB/TNNC1 signaling to promote ovarian cancer cell motility and invasion. Targeting stromal MFAP5 with siRNA in chitosan nanoparticles significantly decreased ovarian tumor growth and metastasis in vivo.","method":"siRNA knockdown, signaling pathway analysis, in vivo mouse tumor model with nanoparticle-delivered siRNA","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro signaling pathway dissection plus in vivo validation, single lab","pmids":["25277212"],"is_preprint":false},{"year":2016,"finding":"MAGP2 (MFAP5) controls Notch signaling in a cell-type-dependent manner through its RGD motif interacting with RGD-binding integrins: in endothelial cells, wild-type MAGP2 suppresses Hes1 promoter activity while a RGD→RGE MAGP2 mutant increases Notch signaling. Inhibition of RGD-binding integrins with soluble RGD peptides or β1/β3 integrin blocking antibodies increased active N1ICD accumulation and Notch responsive promoter activity independently of changes in Notch1, Jag1, or Dll4 expression.","method":"Hes1 promoter luciferase reporter assay, RGD→RGE point mutagenesis, soluble RGD peptide inhibition, integrin blocking antibodies, N1ICD accumulation assay","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus multiple pharmacological inhibitor approaches plus antibody blocking, mechanistically dissecting the integrin-Notch axis; single lab but multiple orthogonal methods","pmids":["26808411"],"is_preprint":false},{"year":2018,"finding":"MFAP5 promotes breast cancer cell proliferation and migration by increasing expression of MMP2 and MMP9 and activating the ERK signaling pathway (p-FAK, p-ERK1/2, p-cJun). Inhibition of MFAP5 suppressed these downstream signaling molecules.","method":"Overexpression and knockdown, Western blot for signaling proteins, cell proliferation and migration assays","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, correlation of MFAP5 levels with downstream signaling molecules by Western blot without direct mechanistic dissection","pmids":["29526753"],"is_preprint":false},{"year":2018,"finding":"MFAP5 is enriched in cancer-associated fibroblast (CAF) secretomes relative to adjacent tissue fibroblasts, and recombinant MFAP5 activates OTSCC cell growth and migration via activation of MAPK and AKT pathways.","method":"Shotgun proteomics of CAF secretomes, in vitro recombinant protein treatment, MAPK/AKT pathway analysis","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — recombinant protein treatment with pathway analysis, proteomic identification of secretion, single lab","pmids":["29681158"],"is_preprint":false},{"year":2019,"finding":"MFAP5 knockdown in cervical cancer cells induces apoptosis through ROS production, activates JNK, reduces Bcl-xl and Bcl-2, and increases Bax and cleaved Caspase-3. MFAP5 knockdown also induces G2/M cell cycle arrest with reduced Cyclin B1, Cyclin D1, and CDK4, and increased p21 and p53. The growth inhibitory effect of MFAP5 knockdown is dependent on ROS production.","method":"siRNA knockdown, ROS measurement, cell cycle analysis, Western blot for apoptosis/cell cycle markers, in vivo xenograft, ROS rescue experiment","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ROS rescue epistasis experiment plus multiple pathway readouts, but single lab single cancer type","pmids":["30454902"],"is_preprint":false},{"year":2019,"finding":"CAF-derived MFAP5 promotes bladder cancer proliferation and metastasis via direct interaction with the NOTCH2 receptor, stimulating N2ICD release and activating NOTCH2/HEY1 signaling. QKI directly downregulates MFAP5 in CAFs as shown by luciferase reporter and EMSA. MFAP5-mediated PI3K-AKT signaling activates the DLL4/NOTCH2 pathway axis. Downregulation of NOTCH2 by shRNA or NRR2Mab antibody reverses the adverse effects of MFAP5 stimulation.","method":"Co-IP (MFAP5 direct interaction with NOTCH2), luciferase reporter assay, EMSA, RNA-sequencing, shRNA knockdown, neutralizing antibody NRR2Mab, in vitro and in vivo rescue experiments","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct protein interaction (co-IP), luciferase + EMSA for upstream regulator, genetic rescue (shRNA + antibody) epistasis; single lab but multiple orthogonal methods","pmids":["32293074"],"is_preprint":false},{"year":2019,"finding":"CAF-secreted MFAP5 drives invasion and migration of MCF7 breast cancer cells via activation of Notch1 signaling, upregulating NICD1 and Slug. Notch1 knockdown in MCF7 cells decreased the ability of MFAP5 to promote invasion and migration.","method":"Proteomic analysis of CAF secretomes, Transwell and wound healing assays, Notch1 knockdown, Western blot for NICD1 and Slug","journal":"Clinical & translational oncology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Notch1 knockdown epistasis confirms pathway dependence, single lab","pmids":["31190277"],"is_preprint":false},{"year":2019,"finding":"MFAP5 promotes basal-like breast cancer metastasis via the TGF-β/Notch pathway: TGF-β or Notch inhibitors significantly reversed tumorigenicity and metastasis of MFAP5-induced BLBC cells in vitro and in vivo.","method":"Overexpression and knockdown, in vitro proliferation/migration/invasion assays, in vivo tail vein metastasis model, TGF-β and Notch pathway inhibitor rescue","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway inhibitor rescue experiments in vitro and in vivo, single lab","pmids":["30899449"],"is_preprint":false},{"year":2019,"finding":"MFAP5 facilitates intrahepatic cholangiocarcinoma (ICC) cell growth and G1-to-S phase transition through regulation of the Notch1 signaling pathway, as revealed by RNA-seq and ATAC-seq of MFAP5-suppressed ICC cells. The Notch signaling inhibitor FLI-06 completely abolished MFAP5-dependent transcriptional programs.","method":"RNA-seq, ATAC-seq, shRNA knockdown, Notch inhibitor (FLI-06) treatment, CCK8 and colony formation assays, cell cycle analysis, xenograft model","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq + ATAC-seq plus pharmacological rescue, single lab but multiple genomic approaches","pmids":["31775892"],"is_preprint":false},{"year":2021,"finding":"Intracellular MAGP2 (MFAP5) directly interacts with urokinase-type plasminogen activator receptor (uPAR) and inhibits lysosomal-mediated degradation of uPAR, thereby increasing uPAR stability. Elevated MAGP2 promotes tumor cell proliferation through uPAR-mediated p38-NF-κB signaling axis activation, enhanced DNA damage repair, and reduction of S-phase cell stagnation.","method":"Co-immunoprecipitation (direct interaction with uPAR), proteomics analysis, lysosomal degradation assay, p38-NF-κB pathway analysis, xenograft model with uPAR knockdown rescue","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP for direct interaction, proteomics, and in vivo rescue by uPAR knockdown; single lab","pmids":["34915136"],"is_preprint":false},{"year":2023,"finding":"MFAP5 deficiency in CAFs downregulates HAS2 and CXCL10 via MFAP5/RCN2/ERK/STAT1 axis in pancreatic cancer, leading to reduced angiogenesis, hyaluronic acid and collagen deposition, increased cytotoxic T cell infiltration, and tumor cell apoptosis. In vivo blockade of CXCL10 with AMG487 partially reverses the pro-tumor effect of MFAP5 overexpression in CAFs.","method":"MFAP5 knockdown in CAFs, Western blot for RCN2/ERK/STAT1 pathway, CXCL10/HAS2 measurement, in vivo tumor models, AMG487 CXCL10 inhibitor rescue","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined signaling axis with in vivo pharmacological rescue; single lab","pmids":["37156839"],"is_preprint":false},{"year":2024,"finding":"MAGP2 (MFAP5) promotes osteogenic differentiation and fracture healing through interaction with LRP5 and activation of β-catenin signaling. MAGP2 upregulates LRP5 expression, and LRP5 knockdown partially reverses MAGP2-promoted osteogenic differentiation and β-catenin activation. β-catenin/TCF4 increases MAGP2 expression by binding to the MAGP2 promoter, creating a feedback loop.","method":"Co-IP (MAGP2-LRP5 interaction), LRP5 knockdown rescue, ALP activity assay, mineralization assay, in vivo fracture mouse model, mRNA sequencing","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus genetic rescue (LRP5 knockdown) plus in vivo model; single lab","pmids":["38348695"],"is_preprint":false},{"year":2025,"finding":"MFAP5 loss in Mfap5-/- mice impairs wound closure, reduces angiogenesis, enhances neutrophil and macrophage influx, and reduces collagen deposition in normal skin. Mfap5-/- fibroblasts exhibit reduced migration, contractility, proliferation, and ECM deposition in vitro, identifying a direct role for MFAP5 in fibroblast behavior relevant to wound healing.","method":"Mfap5-/- mouse wound healing model, single-cell RNA sequencing, in vitro fibroblast isolation and functional assays (migration, contractility, proliferation, ECM deposition), mRNA sequencing","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo genetic knockout with defined phenotypes plus in vitro cellular validation with multiple functional readouts; single lab but comprehensive approach","pmids":["41348119"],"is_preprint":false},{"year":2025,"finding":"MFAP5 engages integrin alpha-5 (ITGA5) to activate ERK/MAPK signaling in odontoblast-lineage cells, promoting odontoblast differentiation and dentin deposition (matrix mineralization).","method":"Single-cell RNA sequencing, functional in vitro differentiation/mineralization assays, MFAP5-ITGA5 interaction and ERK/MAPK signaling pathway analysis","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, in vitro functional assays with pathway analysis but MFAP5-ITGA5 interaction not rigorously validated by co-IP/pulldown in abstract","pmids":["41516268"],"is_preprint":false},{"year":2025,"finding":"MFAP5 promotes stemness features of NSCLC cells by inducing degradation of FBW7 (a tumor suppressor), which stabilizes Sox9 (a cancer stem cell protein). MFAP5 knockdown increased FBW7 levels and accelerated Sox9 degradation (CHX chase assay). Sox9 overexpression rescued growth/stemness inhibition caused by MFAP5 knockdown.","method":"MFAP5 overexpression/knockdown, Western blot for FBW7 and Sox9, CHX degradation assay, Sox9 overexpression rescue, clone formation and sphere culture assays","journal":"Current pharmaceutical biotechnology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, mechanistic cascade inferred from protein level changes and rescue; no direct MFAP5-FBW7 interaction shown in abstract","pmids":["38415489"],"is_preprint":false},{"year":2019,"finding":"Anti-MFAP5 antibody clone 130A downregulates MFAP5-induced collagen production in CAFs, suppresses intratumoral microvessel leakiness, and enhances paclitaxel bioavailability in ovarian and pancreatic cancer mouse models. Epitope mapping identified a common epitope shared between human and murine MFAP5.","method":"Hybridoma antibody development, Octet RED384 binding kinetics, epitope mapping, in vitro collagen production assay, in vivo tumor-bearing mouse models","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined functional antibody with in vitro and in vivo validation of collagen and vascular phenotypes; single lab","pmids":["31332047"],"is_preprint":false}],"current_model":"MFAP5 (MAGP-2) is a small extracellular matrix glycoprotein that localizes to fibrillin-containing microfibrils via a conserved cysteine-rich matrix-binding domain (whose microfibril association is positively regulated by proprotein convertase cleavage), where it directly interacts with fibrillin-1 and fibrillin-2 to support elastic fiber assembly by facilitating tropoelastin deposition onto microfibrils; outside the ECM structural role, MFAP5 modulates cell signaling through multiple mechanisms: it binds EGF-like repeats of Notch1 and the DSL ligand Jagged1 to trigger extracellular domain shedding and context-dependent Notch activation or repression (with cell-type specificity dependent on RGD-integrin interactions), binds active TGFβ1, TGFβ2, and BMP2, and in cancer contexts activates FAK/CREB/TNNC1, MAPK/ERK, AKT, and p38-NF-κB signaling to promote tumor cell motility, invasion, and survival, while intracellularly stabilizing uPAR by blocking lysosomal degradation; loss of MFAP5 in mice causes neutropenia, age-dependent aortic dilation when combined with MAGP1 loss, and impaired wound healing with reduced fibroblast migration, collagen deposition, and angiogenesis."},"narrative":{"mechanistic_narrative":"MFAP5 (MAGP-2) is a small cysteine-rich extracellular matrix glycoprotein of elastin-associated microfibrils that bridges structural matrix assembly and cell signaling [PMID:8557636, PMID:9671438]. It binds fibrillin-1 and fibrillin-2 through a core domain containing seven conserved cysteines, docking onto a calcium-binding EGF-like region near the fibrillin C-terminus, and this microfibril association requires a dedicated matrix-binding domain that is positively regulated by proprotein convertase cleavage [PMID:12122015, PMID:25153248]. Through this localization MFAP5 stimulates elastic fiber assembly independently of tropoelastin levels and independently of its RGD motif [PMID:17099216]. Beyond its structural role, MFAP5 is a multifunctional modulator of Notch signaling: it binds the EGF-like repeats of Notch1 and the DSL ligand Jagged1, promoting metalloproteinase-dependent shedding of the Jagged1 ectodomain and furin-dependent release of the Notch1 extracellular domain [PMID:15788413, PMID:16492672]. The signaling output is context-dependent—it represses Notch and promotes angiogenic sprouting in endothelial cells while activating Notch in heterologous cells, a cell-type specificity governed by its RGD motif engaging RGD-binding integrins [PMID:18417156, PMID:26808411]. MFAP5 also binds active TGFβ1, TGFβ2, and BMP2 [PMID:23963447]. In cancer-associated fibroblasts and tumor cells it activates FAK/CREB/TNNC1, NOTCH2/HEY1, and TGF-β/Notch programs to drive proliferation, motility, invasion, and metastasis, and it stabilizes intracellular uPAR by blocking its lysosomal degradation [PMID:25277212, PMID:32293074, PMID:34915136]. In genetic loss-of-function studies, Mfap5-/- mice show neutropenia, and combined loss with MAGP1 causes age-dependent aortic dilation, while MFAP5 loss also impairs wound healing with reduced fibroblast migration, collagen deposition, and angiogenesis [PMID:23963447, PMID:41348119]. MFAP5 additionally promotes osteogenic differentiation via LRP5/β-catenin signaling [PMID:38348695].","teleology":[{"year":1996,"claim":"Established MFAP5 as a discrete microfibril component distinct from its homolog MAGP-1, defining the cysteine-rich core and RGD motif that would later prove functionally central.","evidence":"Peptide sequencing, cDNA cloning, and immunoelectron microscopy of elastin-associated microfibrils","pmids":["8557636"],"confidence":"High","gaps":["Function of the RGD motif not yet defined","Binding partners not yet identified"]},{"year":1998,"claim":"Mapped the tissue distribution of MFAP5 on fibrillin microfibrils, showing it is more restricted than MAGP-1 and predicting non-redundant roles.","evidence":"Immunoelectron microscopy and Northern blotting across multiple tissues","pmids":["9671438"],"confidence":"High","gaps":["Does not establish the molecular basis of the restricted distribution","No functional consequence tested"]},{"year":2002,"claim":"Identified the direct fibrillin-1/fibrillin-2 binding interaction and mapped it to the conserved cysteine core, defining how MFAP5 anchors to microfibrils at a site distinct from MAGP-1.","evidence":"Yeast two-hybrid with deletion mapping and reciprocal co-IP in COS-7 cells","pmids":["12122015","11796718"],"confidence":"High","gaps":["Stoichiometry and affinity not quantified","A single amino acid change blocking matrix association left mechanism of matrix targeting incomplete"]},{"year":2006,"claim":"Demonstrated that MFAP5 actively stimulates elastic fiber assembly rather than serving as a passive scaffold, and excluded integrin/RGD involvement in this structural function.","evidence":"Doxycycline-regulated overexpression with electron microscopy and RGD mutagenesis","pmids":["17099216"],"confidence":"High","gaps":["Molecular mechanism by which MFAP5 promotes tropoelastin deposition not resolved","Single in vitro cell system"]},{"year":2006,"claim":"Revealed MFAP5's signaling role by showing it binds Notch1 and Jagged1 EGF-like repeats and triggers ectodomain shedding/release, distinguishing it functionally from MAGP-1.","evidence":"Yeast two-hybrid, co-IP, shedding assays with metalloproteinase inhibitor, and Notch reporter assays with cleavage-requirement dissection","pmids":["15788413","16492672"],"confidence":"High","gaps":["Whether shedding occurs at physiological MFAP5 levels in vivo unclear","Distinction between activation and repression not yet explained"]},{"year":2016,"claim":"Resolved the context-dependence of Notch modulation, showing the RGD–integrin axis determines whether MFAP5 represses or activates Notch in a given cell type.","evidence":"Hes1 reporter assays with RGD→RGE mutagenesis, soluble RGD peptides, and β1/β3 integrin blocking antibodies","pmids":["18417156","26808411"],"confidence":"High","gaps":["Specific integrin heterodimer not pinned to each cell context","Mechanistic link between integrin engagement and Notch processing incomplete"]},{"year":2013,"claim":"Provided in vivo genetic loss-of-function evidence for MFAP5 in hematopoiesis and vessel integrity and showed it binds active growth factors, establishing a TGF-β/BMP reservoir role.","evidence":"Mfap5-/- and MAGP1;MAGP2 double-knockout mice with blood counts and vascular compliance, plus solid-phase TGF-β/BMP2 binding assays","pmids":["23963447"],"confidence":"High","gaps":["Mechanism linking MFAP5 to neutrophil numbers unknown","Whether growth-factor sequestration drives the vascular phenotype untested"]},{"year":2021,"claim":"Expanded MFAP5 function to an intracellular, signaling-stabilizing role by showing it binds and protects uPAR from lysosomal degradation to drive tumor proliferation.","evidence":"Co-IP, proteomics, lysosomal degradation assay, and xenograft with uPAR knockdown rescue","pmids":["34915136"],"confidence":"Medium","gaps":["How a secreted ECM protein accesses an intracellular pool not clarified","Single lab and cancer context"]},{"year":2023,"claim":"Consolidated MFAP5 as a cancer-associated fibroblast effector across tumor types, activating multiple signaling axes (FAK/CREB/TNNC1, NOTCH2/HEY1, TGF-β/Notch, RCN2/ERK/STAT1) to remodel stroma and promote progression.","evidence":"siRNA/shRNA knockdown, co-IP for NOTCH2, RNA-seq/ATAC-seq, pathway inhibitor and neutralizing-antibody rescue across multiple cancer models","pmids":["25277212","32293074","31775892","37156839"],"confidence":"Medium","gaps":["Receptor usage differs across studies without unifying mechanism","Direct vs indirect pathway engagement not always distinguished"]},{"year":2025,"claim":"Defined MFAP5's role in fibroblast-driven tissue repair and matrix mineralization, linking the gene to wound healing, osteogenesis (LRP5/β-catenin), and dentin formation.","evidence":"Mfap5-/- wound-healing model with single-cell RNA-seq and fibroblast functional assays; co-IP and LRP5 knockdown rescue for osteogenesis","pmids":["41348119","38348695","41516268"],"confidence":"High","gaps":["Whether wound-healing and osteogenic effects share a common receptor unresolved","ITGA5 interaction not rigorously validated"]},{"year":null,"claim":"How MFAP5's distinct structural (microfibril/elastic fiber), growth-factor-reservoir, and receptor-signaling activities are integrated and partitioned across cell types and intracellular versus extracellular pools remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of MFAP5 bound to its receptors","Mechanism switching MFAP5 between Notch activation and repression not fully defined","No human Mendelian disease link established in the corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,1,6]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,5,8,11]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[4,5,15]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[2]}],"localization":[{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[0,1,6,9]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[13,15,16]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4,5,11]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,7,11,15]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[2,6,9]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,15,19,20]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[21,22]}],"complexes":["fibrillin microfibril"],"partners":["FBN1","FBN2","NOTCH1","JAG1","NOTCH2","PLAUR","LRP5","ITGA5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13361","full_name":"Microfibrillar-associated protein 5","aliases":["MP25","Microfibril-associated glycoprotein 2","MAGP-2"],"length_aa":173,"mass_kda":19.6,"function":"May play a role in hematopoiesis. In the cardiovascular system, could regulate growth factors or participate in cell signaling in maintaining large vessel integrity (By similarity). Component of the elastin-associated microfibrils (PubMed:8557636)","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/Q13361/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MFAP5","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MFAP5","total_profiled":1310},"omim":[{"mim_id":"616166","title":"AORTIC ANEURYSM, FAMILIAL THORACIC 9; AAT9","url":"https://www.omim.org/entry/616166"},{"mim_id":"607086","title":"AORTIC ANEURYSM, FAMILIAL THORACIC 1; AAT1","url":"https://www.omim.org/entry/607086"},{"mim_id":"601103","title":"MICROFIBRILLAR-ASSOCIATED PROTEIN 5; MFAP5","url":"https://www.omim.org/entry/601103"},{"mim_id":"301870","title":"BIGLYCAN; BGN","url":"https://www.omim.org/entry/301870"},{"mim_id":"156790","title":"MICROFIBRILLAR-ASSOCIATED PROTEIN 2; MFAP2","url":"https://www.omim.org/entry/156790"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"endometrium 1","ntpm":184.8}],"url":"https://www.proteinatlas.org/search/MFAP5"},"hgnc":{"alias_symbol":["MAGP2","MP25"],"prev_symbol":[]},"alphafold":{"accession":"Q13361","domains":[{"cath_id":"-","chopping":"84-151","consensus_level":"medium","plddt":88.7426,"start":84,"end":151}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13361","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13361-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13361-F1-predicted_aligned_error_v6.png","plddt_mean":64.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MFAP5","jax_strain_url":"https://www.jax.org/strain/search?query=MFAP5"},"sequence":{"accession":"Q13361","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13361.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13361/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13361"}},"corpus_meta":[{"pmid":"8557636","id":"PMC_8557636","title":"Further characterization of proteins associated with elastic fiber microfibrils including the molecular cloning of MAGP-2 (MP25).","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8557636","citation_count":130,"is_preprint":false},{"pmid":"25277212","id":"PMC_25277212","title":"Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25277212","citation_count":113,"is_preprint":false},{"pmid":"16492672","id":"PMC_16492672","title":"Microfibrillar proteins MAGP-1 and MAGP-2 induce Notch1 extracellular domain dissociation and receptor activation.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16492672","citation_count":106,"is_preprint":false},{"pmid":"25434006","id":"PMC_25434006","title":"MFAP5 loss-of-function mutations underscore the involvement of matrix alteration in the pathogenesis of familial thoracic aortic aneurysms and dissections.","date":"2014","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25434006","citation_count":96,"is_preprint":false},{"pmid":"9671438","id":"PMC_9671438","title":"Microfibril-associated glycoprotein-2 (MAGP-2) is specifically associated with fibrillin-containing microfibrils but exhibits more restricted patterns of tissue localization and developmental expression than its structural relative MAGP-1.","date":"1998","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/9671438","citation_count":80,"is_preprint":false},{"pmid":"29681158","id":"PMC_29681158","title":"Proteomic Analysis of Cancer-Associated Fibroblasts Reveals a Paracrine Role for MFAP5 in Human Oral Tongue Squamous Cell Carcinoma.","date":"2018","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/29681158","citation_count":77,"is_preprint":false},{"pmid":"18417156","id":"PMC_18417156","title":"Microfibril-associate glycoprotein-2 (MAGP-2) promotes angiogenic cell sprouting by blocking notch signaling in endothelial cells.","date":"2008","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/18417156","citation_count":67,"is_preprint":false},{"pmid":"12122015","id":"PMC_12122015","title":"Microfibril-associated glycoprotein-2 interacts with fibrillin-1 and fibrillin-2 suggesting a role for MAGP-2 in elastic fiber assembly.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12122015","citation_count":63,"is_preprint":false},{"pmid":"31332047","id":"PMC_31332047","title":"Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31332047","citation_count":60,"is_preprint":false},{"pmid":"23963447","id":"PMC_23963447","title":"Microfibril-associated glycoprotein 2 (MAGP2) loss of function has pleiotropic effects in vivo.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23963447","citation_count":59,"is_preprint":false},{"pmid":"17099216","id":"PMC_17099216","title":"Microfibril-associated MAGP-2 stimulates elastic fiber assembly.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17099216","citation_count":53,"is_preprint":false},{"pmid":"29524629","id":"PMC_29524629","title":"Microfibril-associated glycoproteins MAGP-1 and MAGP-2 in disease.","date":"2018","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29524629","citation_count":50,"is_preprint":false},{"pmid":"15788413","id":"PMC_15788413","title":"The extracellular matrix protein MAGP-2 interacts with Jagged1 and induces its shedding from the cell surface.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15788413","citation_count":48,"is_preprint":false},{"pmid":"32293074","id":"PMC_32293074","title":"CAFs-derived MFAP5 promotes bladder cancer malignant behavior through NOTCH2/HEY1 signaling.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32293074","citation_count":46,"is_preprint":false},{"pmid":"26054006","id":"PMC_26054006","title":"MFAP5 is related to obesity-associated adipose tissue and extracellular matrix remodeling and inflammation.","date":"2015","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26054006","citation_count":40,"is_preprint":false},{"pmid":"37344903","id":"PMC_37344903","title":"Interactions between MFAP5 + fibroblasts and tumor-infiltrating myeloid cells shape the malignant microenvironment of colorectal cancer.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37344903","citation_count":39,"is_preprint":false},{"pmid":"11796718","id":"PMC_11796718","title":"Identification of a matrix-binding domain in MAGP1 and MAGP2 and intracellular localization of alternative splice forms.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11796718","citation_count":39,"is_preprint":false},{"pmid":"29526753","id":"PMC_29526753","title":"MFAP5 promotes tumor progression and bone metastasis by regulating ERK/MMP signaling pathways in breast cancer.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29526753","citation_count":37,"is_preprint":false},{"pmid":"30454902","id":"PMC_30454902","title":"MFAP5 suppression inhibits migration/invasion, regulates cell cycle and induces apoptosis via promoting ROS production in cervical cancer.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30454902","citation_count":35,"is_preprint":false},{"pmid":"30899449","id":"PMC_30899449","title":"MFAP5 promotes basal-like breast cancer progression by activating the EMT program.","date":"2019","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/30899449","citation_count":35,"is_preprint":false},{"pmid":"24496384","id":"PMC_24496384","title":"Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators.","date":"2014","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24496384","citation_count":35,"is_preprint":false},{"pmid":"37156839","id":"PMC_37156839","title":"Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix.","date":"2023","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/37156839","citation_count":33,"is_preprint":false},{"pmid":"31775892","id":"PMC_31775892","title":"MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathway.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31775892","citation_count":32,"is_preprint":false},{"pmid":"26808411","id":"PMC_26808411","title":"MAGP2 controls Notch via interactions with RGD binding integrins: Identification of a novel ECM-integrin-Notch signaling axis.","date":"2016","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/26808411","citation_count":31,"is_preprint":false},{"pmid":"31190277","id":"PMC_31190277","title":"Stromal fibroblast-derived MFAP5 promotes the invasion and migration of breast cancer cells via Notch1/slug signaling.","date":"2019","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/31190277","citation_count":25,"is_preprint":false},{"pmid":"32047565","id":"PMC_32047565","title":"Hypoxia-induced MFAP5 Promotes Tumor Migration and Invasion via AKT Pathway in Head and Neck Squamous Cell Carcinoma.","date":"2020","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32047565","citation_count":16,"is_preprint":false},{"pmid":"31426719","id":"PMC_31426719","title":"MAGP2, a Component of Extracellular Matrix, Is Upregulated in Colorectal Cancer and Negatively Modulated by miR-200b-3p.","date":"2019","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/31426719","citation_count":14,"is_preprint":false},{"pmid":"31422503","id":"PMC_31422503","title":"Loss of microfibril-associated protein 5 (MFAP5) expression in colon cancer stroma.","date":"2019","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31422503","citation_count":13,"is_preprint":false},{"pmid":"37217152","id":"PMC_37217152","title":"Cancer-associated fibroblasts in the invasive tumour front promote the metastasis of oral squamous cell carcinoma through MFAP5 upregulation.","date":"2023","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/37217152","citation_count":13,"is_preprint":false},{"pmid":"35240498","id":"PMC_35240498","title":"High glucose stimulating ECM remodeling and an inflammatory phenotype in the IPFP via upregulation of MFAP5 expression.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35240498","citation_count":11,"is_preprint":false},{"pmid":"9792630","id":"PMC_9792630","title":"The exon structure of the human MAGP-2 gene. Similarity with the MAGP-1 gene is confined to two exons encoding a cysteine-rich region.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9792630","citation_count":11,"is_preprint":false},{"pmid":"34419964","id":"PMC_34419964","title":"Levofloxacin exerts broad-spectrum anticancer activity via regulation of THBS1, LAPTM5, SRD5A3, MFAP5 and P4HA1.","date":"2022","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/34419964","citation_count":10,"is_preprint":false},{"pmid":"10723723","id":"PMC_10723723","title":"Organization of the mouse microfibril-associated glycoprotein-2 (MAGP-2) gene.","date":"2000","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/10723723","citation_count":9,"is_preprint":false},{"pmid":"34915136","id":"PMC_34915136","title":"MAGP2 induces tumor progression by enhancing uPAR-mediated cell proliferation.","date":"2021","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/34915136","citation_count":8,"is_preprint":false},{"pmid":"25153248","id":"PMC_25153248","title":"Binding of MAGP2 to microfibrils is regulated by proprotein convertase cleavage.","date":"2014","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25153248","citation_count":8,"is_preprint":false},{"pmid":"39531783","id":"PMC_39531783","title":"Identification of cancer-associated fibrolast subtypes and distinctive role of MFAP5 in CT-detected extramural venous invasion in gastric cancer.","date":"2024","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39531783","citation_count":7,"is_preprint":false},{"pmid":"39463228","id":"PMC_39463228","title":"Upregulation of MFAP5 Enhances COL1A1 Expression, Promoting Epithelial-Mesenchymal Transition in Gastric Cancer Cells.","date":"2024","source":"Discovery medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39463228","citation_count":6,"is_preprint":false},{"pmid":"39524442","id":"PMC_39524442","title":"High-resolution subtyping of fibroblasts in gastric cancer reveals diversity among fibroblast subsets and an association between the MFAP5-fibroblast subset and immunotherapy.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39524442","citation_count":5,"is_preprint":false},{"pmid":"30320661","id":"PMC_30320661","title":"Immunohistochemical Expression of Microfibrillar-associated Protein 5 (MFAP5) in Invasive Breast Carcinoma of No Special Type.","date":"2019","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/30320661","citation_count":5,"is_preprint":false},{"pmid":"32895766","id":"PMC_32895766","title":"Reduced MFAP5 expression in stroma of gallbladder adenocarcinoma and its potential diagnostic utility.","date":"2020","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32895766","citation_count":5,"is_preprint":false},{"pmid":"40020327","id":"PMC_40020327","title":"Overexpression of MFAP5 inhibits the progression of papillary thyroid cancer and aerobic glycolysis by regulating the EFEMP2/Wnt/β-catenin pathway.","date":"2025","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/40020327","citation_count":3,"is_preprint":false},{"pmid":"38348695","id":"PMC_38348695","title":"MAGP2 promotes osteogenic differentiation during fracture healing through its crosstalk with the β-catenin pathway.","date":"2024","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/38348695","citation_count":2,"is_preprint":false},{"pmid":"38415489","id":"PMC_38415489","title":"MFAP5 Strengthened the Stem Cell Features of Non-small Cell Lung Cancer Cells by Regulating the FBW/Sox9 Axis.","date":"2025","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/38415489","citation_count":2,"is_preprint":false},{"pmid":"41677363","id":"PMC_41677363","title":"Biodegradable Carbonate Nanogels Loaded with Anti MFAP-5 siRNA for Anti-stromal Therapy of Hepatocellular Carcinoma.","date":"2026","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41677363","citation_count":2,"is_preprint":false},{"pmid":"41348119","id":"PMC_41348119","title":"Loss of MFAP5 and Its Effect on Skin Homeostasis and Wound Healing.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/41348119","citation_count":1,"is_preprint":false},{"pmid":"41205579","id":"PMC_41205579","title":"Integrated bulk and single-cell RNA profiling implicates MFAP5+ CAFs in potential role in peritoneal metastasis of gastric cancer.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/41205579","citation_count":0,"is_preprint":false},{"pmid":"39759103","id":"PMC_39759103","title":"MFAP5 inhibits the malignant progression of endometrial cancer cells in vitro.","date":"2024","source":"Open life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39759103","citation_count":0,"is_preprint":false},{"pmid":"38743016","id":"PMC_38743016","title":"Loci cg06256735 and cg15815843 in the MFAP5 gene regulatory regions are hypomethylated in varicose veins apparently due to active demethylation.","date":"2024","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/38743016","citation_count":0,"is_preprint":false},{"pmid":"41112301","id":"PMC_41112301","title":"MFAP5 as a promising biomarker for connective tissue disease-associated interstitial lung disease.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41112301","citation_count":0,"is_preprint":false},{"pmid":"41443738","id":"PMC_41443738","title":"[The expression of MFAP5 in ovarian cancer and its effect on cancer cell proliferation, metastasis and drug resistance].","date":"2025","source":"Zhonghua zhong liu za zhi [Chinese journal of oncology]","url":"https://pubmed.ncbi.nlm.nih.gov/41443738","citation_count":0,"is_preprint":false},{"pmid":"38031457","id":"PMC_38031457","title":"MFAP5 variant-induced multiple giant thoracic aortic aneurysm.","date":"2023","source":"Cardiology in the young","url":"https://pubmed.ncbi.nlm.nih.gov/38031457","citation_count":0,"is_preprint":false},{"pmid":"41051977","id":"PMC_41051977","title":"Significance of MFAP5, IMP3 and Desmin Expression as Diagnostic Biomarkers for Colorectal Cancers in Biopsy Specimens.","date":"2025","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/41051977","citation_count":0,"is_preprint":false},{"pmid":"41995689","id":"PMC_41995689","title":"Deciphering MFAP5+ Fibroblasts in Pancreatic Cancer Progression via Multi-Regional Single-Cell RNA Sequencing With Experimental Validation.","date":"2026","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/41995689","citation_count":0,"is_preprint":false},{"pmid":"41516268","id":"PMC_41516268","title":"MFAP5 Activates ITGA5 to Drive Tooth Germ Mineralization Through the MAPK/ERK Pathway: Insights from Single-Cell Transcriptomics.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41516268","citation_count":0,"is_preprint":false},{"pmid":"41666500","id":"PMC_41666500","title":"Combination of serum TBL1XR1, MFAP5, and PSA as diagnostic biomarkers for prostate cancer.","date":"2026","source":"Clinics (Sao Paulo, Brazil)","url":"https://pubmed.ncbi.nlm.nih.gov/41666500","citation_count":0,"is_preprint":false},{"pmid":"40699854","id":"PMC_40699854","title":"Chronic Exposure of Renal Progenitor Cells (HRTPT) to As (III) Implicates Microfibril Associated Protein 5 (MFAP5) in the Activation of Carcinoembryonic Antigen Related Cell Adhesion Molecules (CEACAM 5 and 6).","date":"2025","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/40699854","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.30.25332433","title":"Large-scale plasma proteomics uncovers preclinical molecular signatures of Parkinson’s disease and overlap with other neurodegenerative disorders","date":"2025-07-30","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.30.25332433","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.06.663336","title":"The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis","date":"2025-07-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.06.663336","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":33833,"output_tokens":7173,"usd":0.104547,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16312,"output_tokens":3892,"usd":0.08943,"stage2_stop_reason":"end_turn"},"total_usd":0.193977,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"MP25 (MAGP-2/MFAP5) was identified as a distinct component of elastin-associated microfibrils by immunofluorescence and immunoelectron microscopy. Its primary structure contains 173 amino acids with significant homology to MAGP-1 confined to a central 60-amino acid cysteine-rich region (7 conserved cysteines), and it contains an RGD motif but lacks proline-, glutamine-, and tyrosine-rich sequences and hydrophobic carboxyl terminus characteristic of MAGP-1, suggesting distinct functions.\",\n      \"method\": \"Peptide sequencing, cDNA cloning, immunofluorescence, immunoelectron microscopy, sequence homology analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct protein isolation, molecular cloning, and immunoelectron microscopy localizing the protein to microfibrils; foundational characterization study\",\n      \"pmids\": [\"8557636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"MAGP-2 (MFAP5) is specifically associated with fibrillin-containing microfibrils in multiple tissues (nuchal ligament, dermis, adventitia, glomerular mesangium, perimysium) as confirmed by immunoelectron microscopy, but has a more restricted tissue distribution than MAGP-1, being absent from medial layer of fetal thoracic aorta and ocular zonule where MAGP-1 is present.\",\n      \"method\": \"Immunoelectron microscopy, immunolocalization, Northern blotting\",\n      \"journal\": \"The journal of histochemistry and cytochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — immunoelectron microscopy providing direct ultrastructural localization, replicated across multiple tissue types\",\n      \"pmids\": [\"9671438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MAGP-2 (MFAP5) specifically interacts with fibrillin-1 and fibrillin-2 via a calcium-binding EGF-like repeat-containing region near the C-terminus of the fibrillins. Binding occurs through a core region of MAGP-2 containing 7 conserved cysteine residues. The fibrillin-1 binding site for MAGP-2 is distinct from the MAGP-1 binding site on fibrillin-1. Interaction was confirmed by co-immunoprecipitation from transfected COS-7 cells.\",\n      \"method\": \"Yeast two-hybrid library screen, deletion analysis, co-immunoprecipitation from transfected COS-7 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — yeast two-hybrid with deletion mapping plus reciprocal co-IP in mammalian cells, two orthogonal methods in one study\",\n      \"pmids\": [\"12122015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MAGP-2 (MFAP5) contains a matrix-binding domain similar to the 54-amino acid C-terminal cysteine-rich domain of MAGP-1, but a single amino acid change prevents MAGP-2 from associating with the ECM in the same mammalian cell model used to demonstrate MAGP-1 matrix binding.\",\n      \"method\": \"Deletion constructs expressed in mammalian cells, GFP fusion localization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional domain analysis in cell system, single lab, but directly identifies the critical domain difference between MAGP-1 and MAGP-2 matrix binding\",\n      \"pmids\": [\"11796718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MAGP-2 (MFAP5) interacts with the Notch ligand Jagged1 via the EGF-like repeats of Jagged1, and promotes shedding of the Jagged1 extracellular domain in a metalloproteinase-dependent manner (blocked by hydroxamate inhibitor BB3103). MAGP-2 also interacts with Jagged2 and Delta1 but does not facilitate their shedding. MAGP-1 interacts with DSL ligands but cannot facilitate Jagged1 shedding.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, conditioned media analysis, metalloproteinase inhibitor treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — yeast two-hybrid plus co-IP plus functional shedding assay, three orthogonal methods in one study\",\n      \"pmids\": [\"15788413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MAGP-2 (MFAP5) directly interacts with the EGF-like repeats of Notch1, and co-expression of MAGP-2 with Notch1 leads to cell surface release of the Notch1 extracellular domain and subsequent activation of Notch signaling. The C-terminal domain of MAGP-2 is required for Notch1 binding and activation. Notch1 extracellular domain release by MAGP-2 requires furin-like cleavage for Notch1 heterodimer formation but does not require subsequent ADAM metalloprotease cleavage.\",\n      \"method\": \"Co-expression studies, Notch signaling reporter assays, domain deletion analysis, cell surface release assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple functional assays including domain mapping and mechanistic dissection of cleavage requirements, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16492672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Microfibril-associated MAGP-2 (MFAP5) stimulates elastic fiber assembly independently of extracellular tropoelastin levels. Electron microscopy showed MAGP-2 specifically associates with microfibrils and elastin globules co-localize with MAGP-2-associated microfibrils. The RGD motif of MAGP-2 is not required for this stimulation of elastic fiber assembly, ruling out integrin receptor binding as the mechanism. MAGP-2 overexpression did not change levels of fibrillin-1, MAGP-1, fibulin-2, fibulin-5, or emilin-1.\",\n      \"method\": \"Doxycycline-regulated conditional overexpression system, immunofluorescence, electron microscopy, mutation analysis of RGD motif\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro functional reconstitution with electron microscopy confirmation and mutagenesis control, single lab\",\n      \"pmids\": [\"17099216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MAGP-2 (MFAP5) promotes angiogenic cell sprouting by antagonizing Notch signaling in endothelial cells specifically: MAGP-2 decreased basal and Jagged1-induced Hes-1 promoter activity and blocked Jagged1-stimulated Notch1 receptor processing in endothelial cells, but increased Hes-1 promoter activity in heterologous cell types. Constitutive activation of Notch blocked MAGP-2-promoted angiogenic sprouting.\",\n      \"method\": \"Hes-1 promoter luciferase reporter assay, Notch1 receptor processing assay in transfected 293T cells, angiogenic sprouting assay, constitutively active Notch rescue experiment\",\n      \"journal\": \"Microvascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays including epistasis (constitutive Notch blocks MAGP-2 effect), single lab but orthogonal approaches\",\n      \"pmids\": [\"18417156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MAGP2 (MFAP5) binds active TGFβ1, TGFβ2, and BMP2 in solid phase binding assays. Loss of MAGP2 in Mfap5-/- mice causes neutropenia (contrasting with monocytopenia in MAGP1-deficient mice), and MAGP1;MAGP2 double knockout mice show age-dependent aortic dilation, indicating shared primary functions of MAGPs in large vessel integrity.\",\n      \"method\": \"Solid phase binding assay, targeted gene inactivation (Mfap5-/- mice), blood cell counts, vascular compliance measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic loss-of-function with defined cellular phenotypes plus direct in vitro binding assay, multiple phenotypes characterized\",\n      \"pmids\": [\"23963447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MFAP5 (MAGP-2) binding to microfibrils requires its conserved Matrix Binding Domain, and this matrix association is positively regulated by proprotein convertase (PC) cleavage of MAGP2. Mutation of the MAGP2 PC consensus site reduced matrix-associated MAGP2. The C-terminal 20-amino acid domain defined by the PC cleavage site also positively modulates matrix localization in a manner requiring the amino-terminal half of the protein.\",\n      \"method\": \"Immunofluorescence co-localization with fibrillin-2 microfibrils, PC consensus site mutagenesis, deletion analysis, overexpression in T3 ovarian cells\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus deletion analysis plus immunofluorescence, single lab, cell-based system\",\n      \"pmids\": [\"25153248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MFAP5 (MAGP-2) activates FAK/CREB/TNNC1 signaling to promote ovarian cancer cell motility and invasion. Targeting stromal MFAP5 with siRNA in chitosan nanoparticles significantly decreased ovarian tumor growth and metastasis in vivo.\",\n      \"method\": \"siRNA knockdown, signaling pathway analysis, in vivo mouse tumor model with nanoparticle-delivered siRNA\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro signaling pathway dissection plus in vivo validation, single lab\",\n      \"pmids\": [\"25277212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MAGP2 (MFAP5) controls Notch signaling in a cell-type-dependent manner through its RGD motif interacting with RGD-binding integrins: in endothelial cells, wild-type MAGP2 suppresses Hes1 promoter activity while a RGD→RGE MAGP2 mutant increases Notch signaling. Inhibition of RGD-binding integrins with soluble RGD peptides or β1/β3 integrin blocking antibodies increased active N1ICD accumulation and Notch responsive promoter activity independently of changes in Notch1, Jag1, or Dll4 expression.\",\n      \"method\": \"Hes1 promoter luciferase reporter assay, RGD→RGE point mutagenesis, soluble RGD peptide inhibition, integrin blocking antibodies, N1ICD accumulation assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus multiple pharmacological inhibitor approaches plus antibody blocking, mechanistically dissecting the integrin-Notch axis; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"26808411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MFAP5 promotes breast cancer cell proliferation and migration by increasing expression of MMP2 and MMP9 and activating the ERK signaling pathway (p-FAK, p-ERK1/2, p-cJun). Inhibition of MFAP5 suppressed these downstream signaling molecules.\",\n      \"method\": \"Overexpression and knockdown, Western blot for signaling proteins, cell proliferation and migration assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, correlation of MFAP5 levels with downstream signaling molecules by Western blot without direct mechanistic dissection\",\n      \"pmids\": [\"29526753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MFAP5 is enriched in cancer-associated fibroblast (CAF) secretomes relative to adjacent tissue fibroblasts, and recombinant MFAP5 activates OTSCC cell growth and migration via activation of MAPK and AKT pathways.\",\n      \"method\": \"Shotgun proteomics of CAF secretomes, in vitro recombinant protein treatment, MAPK/AKT pathway analysis\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — recombinant protein treatment with pathway analysis, proteomic identification of secretion, single lab\",\n      \"pmids\": [\"29681158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MFAP5 knockdown in cervical cancer cells induces apoptosis through ROS production, activates JNK, reduces Bcl-xl and Bcl-2, and increases Bax and cleaved Caspase-3. MFAP5 knockdown also induces G2/M cell cycle arrest with reduced Cyclin B1, Cyclin D1, and CDK4, and increased p21 and p53. The growth inhibitory effect of MFAP5 knockdown is dependent on ROS production.\",\n      \"method\": \"siRNA knockdown, ROS measurement, cell cycle analysis, Western blot for apoptosis/cell cycle markers, in vivo xenograft, ROS rescue experiment\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ROS rescue epistasis experiment plus multiple pathway readouts, but single lab single cancer type\",\n      \"pmids\": [\"30454902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CAF-derived MFAP5 promotes bladder cancer proliferation and metastasis via direct interaction with the NOTCH2 receptor, stimulating N2ICD release and activating NOTCH2/HEY1 signaling. QKI directly downregulates MFAP5 in CAFs as shown by luciferase reporter and EMSA. MFAP5-mediated PI3K-AKT signaling activates the DLL4/NOTCH2 pathway axis. Downregulation of NOTCH2 by shRNA or NRR2Mab antibody reverses the adverse effects of MFAP5 stimulation.\",\n      \"method\": \"Co-IP (MFAP5 direct interaction with NOTCH2), luciferase reporter assay, EMSA, RNA-sequencing, shRNA knockdown, neutralizing antibody NRR2Mab, in vitro and in vivo rescue experiments\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein interaction (co-IP), luciferase + EMSA for upstream regulator, genetic rescue (shRNA + antibody) epistasis; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"32293074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CAF-secreted MFAP5 drives invasion and migration of MCF7 breast cancer cells via activation of Notch1 signaling, upregulating NICD1 and Slug. Notch1 knockdown in MCF7 cells decreased the ability of MFAP5 to promote invasion and migration.\",\n      \"method\": \"Proteomic analysis of CAF secretomes, Transwell and wound healing assays, Notch1 knockdown, Western blot for NICD1 and Slug\",\n      \"journal\": \"Clinical & translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Notch1 knockdown epistasis confirms pathway dependence, single lab\",\n      \"pmids\": [\"31190277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MFAP5 promotes basal-like breast cancer metastasis via the TGF-β/Notch pathway: TGF-β or Notch inhibitors significantly reversed tumorigenicity and metastasis of MFAP5-induced BLBC cells in vitro and in vivo.\",\n      \"method\": \"Overexpression and knockdown, in vitro proliferation/migration/invasion assays, in vivo tail vein metastasis model, TGF-β and Notch pathway inhibitor rescue\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway inhibitor rescue experiments in vitro and in vivo, single lab\",\n      \"pmids\": [\"30899449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MFAP5 facilitates intrahepatic cholangiocarcinoma (ICC) cell growth and G1-to-S phase transition through regulation of the Notch1 signaling pathway, as revealed by RNA-seq and ATAC-seq of MFAP5-suppressed ICC cells. The Notch signaling inhibitor FLI-06 completely abolished MFAP5-dependent transcriptional programs.\",\n      \"method\": \"RNA-seq, ATAC-seq, shRNA knockdown, Notch inhibitor (FLI-06) treatment, CCK8 and colony formation assays, cell cycle analysis, xenograft model\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq + ATAC-seq plus pharmacological rescue, single lab but multiple genomic approaches\",\n      \"pmids\": [\"31775892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Intracellular MAGP2 (MFAP5) directly interacts with urokinase-type plasminogen activator receptor (uPAR) and inhibits lysosomal-mediated degradation of uPAR, thereby increasing uPAR stability. Elevated MAGP2 promotes tumor cell proliferation through uPAR-mediated p38-NF-κB signaling axis activation, enhanced DNA damage repair, and reduction of S-phase cell stagnation.\",\n      \"method\": \"Co-immunoprecipitation (direct interaction with uPAR), proteomics analysis, lysosomal degradation assay, p38-NF-κB pathway analysis, xenograft model with uPAR knockdown rescue\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP for direct interaction, proteomics, and in vivo rescue by uPAR knockdown; single lab\",\n      \"pmids\": [\"34915136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MFAP5 deficiency in CAFs downregulates HAS2 and CXCL10 via MFAP5/RCN2/ERK/STAT1 axis in pancreatic cancer, leading to reduced angiogenesis, hyaluronic acid and collagen deposition, increased cytotoxic T cell infiltration, and tumor cell apoptosis. In vivo blockade of CXCL10 with AMG487 partially reverses the pro-tumor effect of MFAP5 overexpression in CAFs.\",\n      \"method\": \"MFAP5 knockdown in CAFs, Western blot for RCN2/ERK/STAT1 pathway, CXCL10/HAS2 measurement, in vivo tumor models, AMG487 CXCL10 inhibitor rescue\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined signaling axis with in vivo pharmacological rescue; single lab\",\n      \"pmids\": [\"37156839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MAGP2 (MFAP5) promotes osteogenic differentiation and fracture healing through interaction with LRP5 and activation of β-catenin signaling. MAGP2 upregulates LRP5 expression, and LRP5 knockdown partially reverses MAGP2-promoted osteogenic differentiation and β-catenin activation. β-catenin/TCF4 increases MAGP2 expression by binding to the MAGP2 promoter, creating a feedback loop.\",\n      \"method\": \"Co-IP (MAGP2-LRP5 interaction), LRP5 knockdown rescue, ALP activity assay, mineralization assay, in vivo fracture mouse model, mRNA sequencing\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus genetic rescue (LRP5 knockdown) plus in vivo model; single lab\",\n      \"pmids\": [\"38348695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MFAP5 loss in Mfap5-/- mice impairs wound closure, reduces angiogenesis, enhances neutrophil and macrophage influx, and reduces collagen deposition in normal skin. Mfap5-/- fibroblasts exhibit reduced migration, contractility, proliferation, and ECM deposition in vitro, identifying a direct role for MFAP5 in fibroblast behavior relevant to wound healing.\",\n      \"method\": \"Mfap5-/- mouse wound healing model, single-cell RNA sequencing, in vitro fibroblast isolation and functional assays (migration, contractility, proliferation, ECM deposition), mRNA sequencing\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic knockout with defined phenotypes plus in vitro cellular validation with multiple functional readouts; single lab but comprehensive approach\",\n      \"pmids\": [\"41348119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MFAP5 engages integrin alpha-5 (ITGA5) to activate ERK/MAPK signaling in odontoblast-lineage cells, promoting odontoblast differentiation and dentin deposition (matrix mineralization).\",\n      \"method\": \"Single-cell RNA sequencing, functional in vitro differentiation/mineralization assays, MFAP5-ITGA5 interaction and ERK/MAPK signaling pathway analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, in vitro functional assays with pathway analysis but MFAP5-ITGA5 interaction not rigorously validated by co-IP/pulldown in abstract\",\n      \"pmids\": [\"41516268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MFAP5 promotes stemness features of NSCLC cells by inducing degradation of FBW7 (a tumor suppressor), which stabilizes Sox9 (a cancer stem cell protein). MFAP5 knockdown increased FBW7 levels and accelerated Sox9 degradation (CHX chase assay). Sox9 overexpression rescued growth/stemness inhibition caused by MFAP5 knockdown.\",\n      \"method\": \"MFAP5 overexpression/knockdown, Western blot for FBW7 and Sox9, CHX degradation assay, Sox9 overexpression rescue, clone formation and sphere culture assays\",\n      \"journal\": \"Current pharmaceutical biotechnology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, mechanistic cascade inferred from protein level changes and rescue; no direct MFAP5-FBW7 interaction shown in abstract\",\n      \"pmids\": [\"38415489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Anti-MFAP5 antibody clone 130A downregulates MFAP5-induced collagen production in CAFs, suppresses intratumoral microvessel leakiness, and enhances paclitaxel bioavailability in ovarian and pancreatic cancer mouse models. Epitope mapping identified a common epitope shared between human and murine MFAP5.\",\n      \"method\": \"Hybridoma antibody development, Octet RED384 binding kinetics, epitope mapping, in vitro collagen production assay, in vivo tumor-bearing mouse models\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined functional antibody with in vitro and in vivo validation of collagen and vascular phenotypes; single lab\",\n      \"pmids\": [\"31332047\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MFAP5 (MAGP-2) is a small extracellular matrix glycoprotein that localizes to fibrillin-containing microfibrils via a conserved cysteine-rich matrix-binding domain (whose microfibril association is positively regulated by proprotein convertase cleavage), where it directly interacts with fibrillin-1 and fibrillin-2 to support elastic fiber assembly by facilitating tropoelastin deposition onto microfibrils; outside the ECM structural role, MFAP5 modulates cell signaling through multiple mechanisms: it binds EGF-like repeats of Notch1 and the DSL ligand Jagged1 to trigger extracellular domain shedding and context-dependent Notch activation or repression (with cell-type specificity dependent on RGD-integrin interactions), binds active TGFβ1, TGFβ2, and BMP2, and in cancer contexts activates FAK/CREB/TNNC1, MAPK/ERK, AKT, and p38-NF-κB signaling to promote tumor cell motility, invasion, and survival, while intracellularly stabilizing uPAR by blocking lysosomal degradation; loss of MFAP5 in mice causes neutropenia, age-dependent aortic dilation when combined with MAGP1 loss, and impaired wound healing with reduced fibroblast migration, collagen deposition, and angiogenesis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MFAP5 (MAGP-2) is a small cysteine-rich extracellular matrix glycoprotein of elastin-associated microfibrils that bridges structural matrix assembly and cell signaling [#0, #1]. It binds fibrillin-1 and fibrillin-2 through a core domain containing seven conserved cysteines, docking onto a calcium-binding EGF-like region near the fibrillin C-terminus, and this microfibril association requires a dedicated matrix-binding domain that is positively regulated by proprotein convertase cleavage [#2, #9]. Through this localization MFAP5 stimulates elastic fiber assembly independently of tropoelastin levels and independently of its RGD motif [#6]. Beyond its structural role, MFAP5 is a multifunctional modulator of Notch signaling: it binds the EGF-like repeats of Notch1 and the DSL ligand Jagged1, promoting metalloproteinase-dependent shedding of the Jagged1 ectodomain and furin-dependent release of the Notch1 extracellular domain [#4, #5]. The signaling output is context-dependent—it represses Notch and promotes angiogenic sprouting in endothelial cells while activating Notch in heterologous cells, a cell-type specificity governed by its RGD motif engaging RGD-binding integrins [#7, #11]. MFAP5 also binds active TGF\\u03b21, TGF\\u03b22, and BMP2 [#8]. In cancer-associated fibroblasts and tumor cells it activates FAK/CREB/TNNC1, NOTCH2/HEY1, and TGF-\\u03b2/Notch programs to drive proliferation, motility, invasion, and metastasis, and it stabilizes intracellular uPAR by blocking its lysosomal degradation [#10, #15, #19]. In genetic loss-of-function studies, Mfap5-/- mice show neutropenia, and combined loss with MAGP1 causes age-dependent aortic dilation, while MFAP5 loss also impairs wound healing with reduced fibroblast migration, collagen deposition, and angiogenesis [#8, #22]. MFAP5 additionally promotes osteogenic differentiation via LRP5/\\u03b2-catenin signaling [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established MFAP5 as a discrete microfibril component distinct from its homolog MAGP-1, defining the cysteine-rich core and RGD motif that would later prove functionally central.\",\n      \"evidence\": \"Peptide sequencing, cDNA cloning, and immunoelectron microscopy of elastin-associated microfibrils\",\n      \"pmids\": [\"8557636\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Function of the RGD motif not yet defined\", \"Binding partners not yet identified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Mapped the tissue distribution of MFAP5 on fibrillin microfibrils, showing it is more restricted than MAGP-1 and predicting non-redundant roles.\",\n      \"evidence\": \"Immunoelectron microscopy and Northern blotting across multiple tissues\",\n      \"pmids\": [\"9671438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish the molecular basis of the restricted distribution\", \"No functional consequence tested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified the direct fibrillin-1/fibrillin-2 binding interaction and mapped it to the conserved cysteine core, defining how MFAP5 anchors to microfibrils at a site distinct from MAGP-1.\",\n      \"evidence\": \"Yeast two-hybrid with deletion mapping and reciprocal co-IP in COS-7 cells\",\n      \"pmids\": [\"12122015\", \"11796718\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and affinity not quantified\", \"A single amino acid change blocking matrix association left mechanism of matrix targeting incomplete\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated that MFAP5 actively stimulates elastic fiber assembly rather than serving as a passive scaffold, and excluded integrin/RGD involvement in this structural function.\",\n      \"evidence\": \"Doxycycline-regulated overexpression with electron microscopy and RGD mutagenesis\",\n      \"pmids\": [\"17099216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which MFAP5 promotes tropoelastin deposition not resolved\", \"Single in vitro cell system\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed MFAP5's signaling role by showing it binds Notch1 and Jagged1 EGF-like repeats and triggers ectodomain shedding/release, distinguishing it functionally from MAGP-1.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, shedding assays with metalloproteinase inhibitor, and Notch reporter assays with cleavage-requirement dissection\",\n      \"pmids\": [\"15788413\", \"16492672\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether shedding occurs at physiological MFAP5 levels in vivo unclear\", \"Distinction between activation and repression not yet explained\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolved the context-dependence of Notch modulation, showing the RGD–integrin axis determines whether MFAP5 represses or activates Notch in a given cell type.\",\n      \"evidence\": \"Hes1 reporter assays with RGD\\u2192RGE mutagenesis, soluble RGD peptides, and \\u03b21/\\u03b23 integrin blocking antibodies\",\n      \"pmids\": [\"18417156\", \"26808411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific integrin heterodimer not pinned to each cell context\", \"Mechanistic link between integrin engagement and Notch processing incomplete\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Provided in vivo genetic loss-of-function evidence for MFAP5 in hematopoiesis and vessel integrity and showed it binds active growth factors, establishing a TGF-\\u03b2/BMP reservoir role.\",\n      \"evidence\": \"Mfap5-/- and MAGP1;MAGP2 double-knockout mice with blood counts and vascular compliance, plus solid-phase TGF-\\u03b2/BMP2 binding assays\",\n      \"pmids\": [\"23963447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking MFAP5 to neutrophil numbers unknown\", \"Whether growth-factor sequestration drives the vascular phenotype untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanded MFAP5 function to an intracellular, signaling-stabilizing role by showing it binds and protects uPAR from lysosomal degradation to drive tumor proliferation.\",\n      \"evidence\": \"Co-IP, proteomics, lysosomal degradation assay, and xenograft with uPAR knockdown rescue\",\n      \"pmids\": [\"34915136\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How a secreted ECM protein accesses an intracellular pool not clarified\", \"Single lab and cancer context\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Consolidated MFAP5 as a cancer-associated fibroblast effector across tumor types, activating multiple signaling axes (FAK/CREB/TNNC1, NOTCH2/HEY1, TGF-\\u03b2/Notch, RCN2/ERK/STAT1) to remodel stroma and promote progression.\",\n      \"evidence\": \"siRNA/shRNA knockdown, co-IP for NOTCH2, RNA-seq/ATAC-seq, pathway inhibitor and neutralizing-antibody rescue across multiple cancer models\",\n      \"pmids\": [\"25277212\", \"32293074\", \"31775892\", \"37156839\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor usage differs across studies without unifying mechanism\", \"Direct vs indirect pathway engagement not always distinguished\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined MFAP5's role in fibroblast-driven tissue repair and matrix mineralization, linking the gene to wound healing, osteogenesis (LRP5/\\u03b2-catenin), and dentin formation.\",\n      \"evidence\": \"Mfap5-/- wound-healing model with single-cell RNA-seq and fibroblast functional assays; co-IP and LRP5 knockdown rescue for osteogenesis\",\n      \"pmids\": [\"41348119\", \"38348695\", \"41516268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether wound-healing and osteogenic effects share a common receptor unresolved\", \"ITGA5 interaction not rigorously validated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How MFAP5's distinct structural (microfibril/elastic fiber), growth-factor-reservoir, and receptor-signaling activities are integrated and partitioned across cell types and intracellular versus extracellular pools remains unresolved.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of MFAP5 bound to its receptors\", \"Mechanism switching MFAP5 between Notch activation and repression not fully defined\", \"No human Mendelian disease link established in the corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 1, 6]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 5, 8, 11]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [4, 5, 15]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [0, 1, 6, 9]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [13, 15, 16]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4, 5, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 7, 11, 15]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [2, 6, 9]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 15, 19, 20]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [21, 22]}\n    ],\n    \"complexes\": [\"fibrillin microfibril\"],\n    \"partners\": [\"FBN1\", \"FBN2\", \"NOTCH1\", \"JAG1\", \"NOTCH2\", \"PLAUR\", \"LRP5\", \"ITGA5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}